Quantum Biopharma Provides Corporate Update
Globe Newswire (Fri, 27-Mar 7:30 PM ET)
TipRanks (Fri, 27-Mar 10:14 AM ET)
Quantum Biopharma's 2025 Audited Year End Financial Results Maintain 'No Going Concern' Status
Globe Newswire (Fri, 27-Mar 8:10 AM ET)
Quantum BioPharma Taps MS Expert to Lead Phase 2 Trial of Lucid-MS
TipRanks (Thu, 26-Mar 8:47 AM ET)
Globe Newswire (Thu, 26-Mar 8:00 AM ET)
Here are the major earnings after the close Tuesday
Seeking Alpha News (Tue, 24-Mar 10:00 AM ET)
Quantum BioPharma Wins Peer-Reviewed Validation for Unbuzzd Alcohol-Relief Supplement
TipRanks (Mon, 23-Mar 8:47 AM ET)
Globe Newswire (Mon, 23-Mar 8:24 AM ET)
Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering
Globe Newswire (Fri, 20-Mar 7:35 PM ET)
Quantum BioPharma Provides Corporate Update
Globe Newswire (Tue, 10-Mar 7:45 PM ET)
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
Quantum Biopharma Ltd. - Class B Subordinate Voting Shares trades on the NASDAQ stock market under the symbol QNTM.
As of March 27, 2026, QNTM stock price climbed to $4.77 with 414,137 million shares trading.
QNTM has a beta of 1.45, meaning it tends to be more sensitive to market movements. QNTM has a correlation of 0.02 to the broad based SPY ETF.
QNTM has a market cap of $18.33 million. This is considered a Sub-Micro Cap stock.
Last quarter Quantum Biopharma Ltd. - Class B Subordinate Voting Shares reported $0 in Revenue and -$.71 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.22.
QNTM has underperformed the market in the last year with a return of -43.1%, while the SPY ETF gained +13.1%. In the last 3 month period, QNTM fell short of the market, returning -42.5%, while SPY returned -7.9%. However, in the most recent 2 weeks QNTM has outperformed the stock market by returning +92.3%, while SPY returned -4.0%.
QNTM support price is $3.36 and resistance is $4.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that QNTM shares will trade within this expected range on the day.
